Description
An agonist of the STING pathway; induces secretion of IFN-β in human PBMCs (EC50 = 130 nM); increases serum levels of IFN-β, IL-6, TNF, and KC/GROα in wild-type mice at 2.5 mg/kg; decreases tumor volume and increases survival in a CT26 murine colorectal cancer model at 3 mg/kg
Formal name: 1-[(2E)-4-[5-(aminocarbonyl)-2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]-7-methoxy-1H-benzimidazol-1-yl]-2-buten-1-yl]-2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]-7-[3-(4-morpholinyl)propoxy]-1H-benzimidazole-5-carboxamide, trihydrochloride
Synonyms:
Molecular weight: 959.3
CAS: 2138299-34-8
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals||Research Area|Cancer||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Immunology & Inflammation|Autoimmunity||Research Area|Immunology & Inflammation|Innate Immunity|Pattern Recognition||Research Area|Immunology & Inflammation|Innate Immunity|STING||Research Area|Infectious Disease